Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576431 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
A Phase 2 study of Solid Tumors Harboring NTRK Fusion, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
- 20
- Study locations
NCT02576431: Completed Phase 2 study of Solid Tumors Harboring NTRK Fusion, sponsored by Bayer.
NCT02576431 is a Phase 2 study of Solid Tumors Harboring NTRK Fusion that has completed, run by Bayer. The registered enrollment target is 215 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02576431, a Phase 2 study of Solid Tumors Harboring NTRK Fusion, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
- 20
- Study locations
Study Summary
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
Conditions Studied
Interventions
- DRUG BAY2757556 (Larotrectinib, Vitrakvi)
Study Locations (20)
California
- Stanford Cancer Center Palo Alto - Palo Alto
- UCLA Health Santa Monica Cancer Care - Santa Monica
Massachusetts
- Mass General Cancer Center - Boston
- Dana-Farber Cancer Institute - Oncology Department - Boston
North Carolina
- UNC Hospitals - UNC Lineberger Comprehensive Cancer Center - Chapel Hill
- Wake Forest Baptist Health - Winston-Salem
Pennsylvania
- Sidney Kimmel Cancer Center - Jefferson Health - Philadelphia
- Fox Chase Cancer Center - Philadelphia
Ciudad Auton. de Buenos Aires
- Hospital Alemán - Buenos Aires
- Centro Estudios Médicos e Invest. Clínicas "Dr. N. Quirno" - Buenos Aires
Florida
- Memorial Cancer Institute at West - Pembroke Pines
Illinois
- The University of Chicago Medical Center - Hyde Park - Hematology & Oncology - Chicago
New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2025-09-29 |
| Phase | Phase 2 |
What the finished NCT02576431 record still lists
NCT02576431 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher).
The record links to 1 condition, with Solid Tumors Harboring NTRK Fusion appearing as the primary indexed condition, and to 1 intervention - of which BAY2757556 (Larotrectinib, Vitrakvi) is the first listed.
NCT02576431 names 20 study sites across 15 states, led by California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02576431 about?
NCT02576431 is a clinical study titled "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors". This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used t...
What is the current status of trial NCT02576431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2015-09-30. Estimated completion is 2025-09-29.
What conditions does trial NCT02576431 study?
This clinical trial studies the following conditions: Solid Tumors Harboring NTRK Fusion.
What interventions are being tested in trial NCT02576431?
The interventions under investigation include: BAY2757556 (Larotrectinib, Vitrakvi) (DRUG).
Who is sponsoring clinical trial NCT02576431?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576431 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors Harboring NTRK Fusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02576431's enrollment target sits among peer trials
215 289th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
ACTIVE NOT RECRUITING · Phase 1
-
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI